November 29, 2007 |
Genentech Inc.'s plan to restrict the availability of Avastin, forcing doctors to prescribe a more expensive drug for eye disease, will cost taxpayers $1 billion to $3 billion a year, according to Sen. Herb Kohl (D-Wis.). Genentech's decision to limit access to the medicine by pharmacies that repackage drugs "is of great concern to me," Kohl said in letters to the Centers for Medicare and Medicaid Services and the Food and Drug Administration.
October 16, 2007 |
Genentech Inc. reported Monday that its third-quarter profit rose nearly 21% from a year earlier, beating Wall Street expectations by a penny a share, thanks to strong sales of the cancer-fighting drug Avastin. The world's second-largest biotechnology company by revenue reported net profit of $685 million, or 64 cents a share, compared with $568 million, or 53 cents, in the same period in 2006. Revenue increased 22% to $2.91 billion.
August 8, 2007 |
Genentech Inc.'s cancer drug Avastin, when given along with chemotherapy, raises the risk of blood clots, according to a company-sponsored study that confirms a hazard already associated with the drug.
July 12, 2007 |
Genentech Inc., one of the world's largest biotechnology companies, continued a positive earnings streak, posting a 41% boost in second-quarter profit Wednesday on sales of its blockbuster cancer drugs. The South San Francisco-based company earned $747 million, or 70 cents a share, compared with $531 million, or 49 cents a share, during the same period a year earlier. Revenue rose to $3 billion from $2.2 billion. The results topped Wall Street expectations.
June 27, 2007 |
Abbott Laboratories Inc. and Genentech Inc. will collaborate to develop and eventually sell two Abbott cancer drugs now in early stages of human testing, the companies said. The drug makers did not disclose financial terms of the global deal, under which they will work together on all aspects of further development of the drugs discovered by Abbott, known as ABT-263 and ABT-869. They will co-promote the drugs in the U.S., with Abbott marketing them overseas.
May 2, 2007 |
Genentech Inc. and Biogen Idec Inc. said their Rituxan cancer drug proved highly effective against multiple sclerosis in a small mid-stage trial, signaling a potential new way of treating the progressive neurological disease. The biotechnology companies said the Phase II trial involved 104 patients with the most common "relapsing-remitting" form of multiple sclerosis -- in which patients have varying levels of recovery and periods of remission between flare-ups of the autoimmune disease.